MCID: GST060
MIFTS: 45

Gastric Cancer, Somatic malady

Categories: Genetic diseases (common), Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Gastric Cancer, Somatic

About this section

Aliases & Descriptions for Gastric Cancer, Somatic:

Name: Gastric Cancer, Somatic 49 11 22
Malignant Neoplasm of Stomach 65
Gastric Cancer Intestinal 67
Stomach Carcinoma 65
 
Gastric Cancer 67
Stomach Cancer 67
Gasc 67

Characteristics:

HPO:

61
gastric cancer, somatic:
Inheritance: somatic mutation


Classifications:



External Ids:

OMIM49 613659
MeSH36 D013274
ICD1027 C16

Summaries for Gastric Cancer, Somatic

About this section
UniProtKB/Swiss-Prot:67 Gastric cancer: A malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease.

MalaCards based summary: Gastric Cancer, Somatic, also known as malignant neoplasm of stomach, is related to gastric cancer risk after h. pylori infection and breast cancer, and has symptoms including stomach cancer An important gene associated with Gastric Cancer, Somatic is MUTYH (MutY DNA Glycosylase), and among its related pathways are Angiogenesis and . Affiliated tissues include small intestine, colon and lymph node, and related mouse phenotypes are muscle and no phenotypic analysis.

OMIM:49 In a review article on the genetic predisposition to gastric cancer, Bevan and Houlston (1999) concluded that several... (613659) more...

Related Diseases for Gastric Cancer, Somatic

About this section

Diseases related to Gastric Cancer, Somatic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 73)
idRelated DiseaseScoreTop Affiliating Genes
1gastric cancer risk after h. pylori infection32.7CDH1, KRAS
2breast cancer28.8APC, CDH1, ERBB2, FGFR2, KRAS, MUT
3stomach cancer12.6
4familial stomach cancer12.5
5stomach cancer, childhood12.4
6gastric cancer12.0
7h. pylori infection10.6
8atypical mole syndrome10.4APC, MUTYH
9breast ductal adenoma10.4CDH1, ERBB2
10familial congenital fourth cranial nerve palsy10.3APC, CDH1, MUTYH
11nasal cavity squamous cell carcinoma10.3CDH1, ERBB2
12cataract-intellectual disability-hypogonadism syndrome10.3KRAS, MUTYH
13gyrate atrophy of choroid and retina with or without ornithinemia10.3ERBB2, FGFR2
14prostatitis10.2
15breast granular cell tumor10.2CDH1, ERBB2
16cervicitis10.2
17adenocarcinoma10.2
18endotheliitis10.2
19gastric adenocarcinoma10.2
20megalencephaly-capillary malformation-polymicrogyria syndrome, somatic10.2MUT, PIK3CA
21cowden syndrome 510.2MUT, PIK3CA
22spermatogenic failure 610.2MUT, PIK3CA
23gastric cardia carcinoma10.2CDH1, ERBB2
24myh9-related disorders10.1APC, KRAS, MUTYH
25pars planitis10.1IRF1, NEU1
26intracranial sinus thrombosis10.1CDH1, KRAS
27ulnar neuropathy10.1APC, KRAS, MUTYH
28acute retinal necrosis syndrome10.1ERBB2, PIK3CA
29organ system benign neoplasm10.1APC, KRAS, MUTYH
30common variable immunodeficiency10.1APC, KRAS, MUTYH
31ehlers-danlos syndrome, type viic10.1APC, GLUL
32congenital disorder of glycosylation, type if10.1ERBB2, NEU1
33anterior horn cell disease10.1KRAS, PIK3CA
34tubular adenocarcinoma10.1CDH1, FGFR2, KRAS
35diffuse idiopathic pulmonary neuroendocrine cell hyperplasia10.1CDH1, ERBB2, KRAS
36hartnup disorder10.1CDH1, ERBB2, KRAS
37hereditary congenital ptosis10.0KRAS, MUTYH
38pancreatic somatostatinoma10.0CDH1, ERBB2, KRAS
39estrogen-receptor negative breast cancer10.0ERBB2, FGFR2, PIK3CA
40brachyolmia10.0CDH1, ERBB2, KRAS
41proctitis10.0CDH1, ERBB2, KRAS
42biliary tract neoplasm10.0APC, CDH1, KRAS, MUTYH
43restless legs syndrome10.0APC, CDH1, KRAS, MUTYH
44zimmermann-laband syndrome 210.0CDH1, ERBB2, PIK3CA
45chondromalacia patellae10.0CDH1, ERBB2, KRAS
46eccrine papillary adenocarcinoma10.0ERBB2, KRAS, PIK3CA
47neuromuscular disease9.9ERBB2, KRAS, PIK3CA
48cavernous hemangioma9.9ERBB2, KRAS, PIK3CA
49desmoid disease, hereditary9.9APC, GLUL, MUTYH
50head and neck carcinoma9.9ERBB2, KRAS

Graphical network of the top 20 diseases related to Gastric Cancer, Somatic:



Diseases related to gastric cancer, somatic

Symptoms for Gastric Cancer, Somatic

About this section


Clinical features from OMIM:

613659

HPO human phenotypes related to Gastric Cancer, Somatic:

id Description Frequency HPO Source Accession
1 stomach cancer HP:0012126

Drugs & Therapeutics for Gastric Cancer, Somatic

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)15 Company Approval Date
1
Cyramza15 41 RAMUCIRUMAB Eli Lilly April 2014
FDA Label: Cyramza
Disease/s that Drug Treats:gastric cancer
Indications and Usage:15 CYRAMZA® is a human vascular endothelial growth factor receptor 2antagonist indicated as a single agent or in combination with paclitaxel, for treatmentof advanced gastric or gastro-esophageal junctionadenocarcinoma, with disease progression on or after priorfluoropyrimidine- or platinum-containing chemotherapy. (1.1) in combination with docetaxel, for treatment of metastatic nonsmallcell lung cancer with disease progression on or afterplatinum-based chemotherapy. Patients with EGFR or ALKgenomic tumor aberrations should have disease progression onFDA-approved therapy for these aberrations prior to receivingCYRAMZA. (1.2) in combination with FOLFIRI, for the treatment of metastaticcolorectal cancer with disease progression on or after priortherapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.(1.3)
DrugBank Targets: -
Mechanism of Action:15 
Target: ligand-stimulated activation of VEGF Receptor 2
Action: inhibitor
FDA: Ramucirumab is a vascular endothelial growth factor receptor 2 antagonist that specifically binds VEGF Receptor2 and blocks binding of VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits ligandstimulatedactivation of VEGF Receptor 2, thereby inhibiting ligand-induced proliferation, and migration of humanendothelial cells. Ramucirumab inhibited angiogenesis in an in vivo animal model.
2
Herceptin15 41 TRASTUZUMAB Genentech October 1998
FDA Label: Herceptin
Disease/s that Drug Treats:Breast cancer/gastric cancer
Indications and Usage:15 Herceptin is a HER2/neu receptor antagonist indicated for: the treatment of HER2 overexpressing breast cancer (1.1, 1.2). the treatment of HER2-overexpressing metastatic gastric orgastroesophageal junction adenocarcinoma (1.3)
DrugBank Targets:13 1. Receptor tyrosine-protein kinase erbB-2;2. Epidermal growth factor receptor;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Complement C1s subcomponent;8. High affinity immunoglobulin gamma Fc receptor I;9. Low affinity immunoglobulin gamma Fc region receptor II-a;10. Low affinity immunoglobulin gamma Fc region receptor II-b;11. Low affinity immunoglobulin gamma Fc region receptor II-c;12. Low affinity immunoglobulin gamma Fc region receptor III-B;13. Low affinity immunoglobulin gamma Fc region receptor III-A
Mechanism of Action:15 
Target: human epidermal growth factor receptor 2 protein (HER2)
Action: binds with strong affinity for immune response
FDA: The HER2 (or c-erbB2) proto-oncogene encodes a transmembrane receptor protein of 185 kDa, which is structurally related to the epidermal growth factor receptor. Herceptin has been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumor cells that overexpress HER2. Herceptin is a mediator of antibody-dependent cellular cytotoxicity (ADCC). In vitro, Herceptin-mediated ADCC has been shown to be preferentially exerted on HER2 overexpressing cancer cells compared with cancer cells that do not overexpress HER2.
3
Iressa15 41 GEFITINIB AstraZeneca May 2003
FDA Label: Iressa
Disease/s that Drug Treats:Non-Small-Cell Lung Cancer
Indications and Usage:15 IRESSA is indicated as monotherapy for the continued treatment of patients with locally advanced ormetastatic non-small cell lung cancer after failure of both platinum-based and docetaxelchemotherapies who are benefiting or have benefited from IRESSA.In light of positive survival data with other agents including another oral EGFR inhibitor, physiciansshould use other treatment options in advanced non-small cell lung cancer patient populations whohave received one or two prior chemotherapy regimens and are refractory or intolerant to their mostrecent regimen. The effectiveness of IRESSA was initially based on objective response rates (see CLINICALPHARMACOLOGY-Clinical Studies section). Subsequent studies intended to demonstrate anincrease in survival have been unsuccessful. Specifically, results from a large placebo-controlledrandomized trial in patients with advanced NSCLC who progressed while receiving or within 90 daysof the last dose of chemotherapy or were intolerant to the most recent prior chemotherapy regimen, didnot show an improvement in survival (see CLINICAL PHARMACOLOGY- Clinical Studiessection).Results from two large, controlled, randomized trials in first-line treatment of non-small cell lungcancer showed no benefit from adding IRESSA to doublet, platinum-based chemotherapy.
DrugBank Targets:13 1. Epidermal growth factor receptor
Mechanism of Action:15 
Target: EGFR tyrosine kinase and other tyrosine kinases
Action: inhibitor
FDA: The mechanism of the clinical antitumor action of gefitinib is not fully characterized. Gefitinibinhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembranecell surface receptors, including the tyrosine kinases associated with the epidermal growth factorreceptor (EGFR-TK). EGFR is expressed on the cell surface of many normal cells and cancer cells.No clinical studies have been performed that demonstrate a correlation between EGFR receptorexpression and response to gefitinib.
4
Iressa15 GEFITINIB AstraZeneca May 2003
FDA Label: Iressa
Disease/s that Drug Treats:Non-Small-Cell Lung Cancer
Indications and Usage:15 IRESSA is indicated as monotherapy for the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies who are benefiting or have benefited from IRESSA. In light of positive survival data with other agents including another oral EGFR inhibitor, physicians should use other treatment options in advanced non-small cell lung cancer patient populations who have received one or two prior chemotherapy regimens and are refractory or intolerant to their most recent regimen. The effectiveness of IRESSA was initially based on objective response rates (see CLINICAL PHARMACOLOGY-Clinical Studies section). Subsequent studies intended to demonstrate an increase in survival have been unsuccessful. Specifically, results from a large placebo-controlled randomized trial in patients with advanced NSCLC who progressed while receiving or within 90 days of the last dose of chemotherapy or were intolerant to the most recent prior chemotherapy regimen, did not show an improvement in survival (see CLINICAL PHARMACOLOGY- Clinical Studies section). Results from two large, controlled, randomized trials in first-line treatment of non-small cell lung cancer showed no benefit from adding IRESSA to doublet, platinum-based chemotherapy.
DrugBank Targets:13 Epidermal growth factor receptor
Mechanism of Action:15 
Target: EGFR tyrosine kinase
Action: inhibitor
FDA: The mechanism of the clinical antitumor action of gefitinib is not fully characterized. Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK). EGFR is expressed on the cell surface of many normal cells and cancer cells. No clinical studies have been performed that demonstrate a correlation between EGFR receptor expression and response to gefitinib.

Drugs for Gastric Cancer, Somatic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
RucaparibPhase 1, Phase 2109931954
Synonyms:
AG-014699
 
AG014699
PF-01367338
rucaparib
2Poly(ADP-ribose) Polymerase InhibitorsPhase 1, Phase 2250

Interventional clinical trials:

idNameStatusNCT IDPhase
1A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)RecruitingNCT01482715Phase 1, Phase 2
2A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA MutationActive, not recruitingNCT02042378Phase 2

Search NIH Clinical Center for Gastric Cancer, Somatic

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Gastric Cancer, Somatic cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Gastric Cancer, Somatic:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Gastric Cancer, Somatic:
Tumor infiltrating lymphocytes, PMIDs: 24329789, 19342963, 23904171, 21498393, 22996367, 19304471, 22555974, 15800326, 23650429, 21325070, 24218514, 8170938, 12242449

Genetic Tests for Gastric Cancer, Somatic

About this section

Genetic tests related to Gastric Cancer, Somatic:

id Genetic test Affiliating Genes
1 Gastric Cancer, Somatic22 KRAS, FGFR2

Anatomical Context for Gastric Cancer, Somatic

About this section

MalaCards organs/tissues related to Gastric Cancer, Somatic:

33
Small intestine, Colon, Lymph node, Lung, Breast, Endothelial

Animal Models for Gastric Cancer, Somatic or affiliated genes

About this section

MGI Mouse Phenotypes related to Gastric Cancer, Somatic:

38 (show all 21)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053698.5APC, ERBB2, FGFR2, KRAS, NEU1, PIK3CA
2MP:00030128.2APC, CDH1, FGFR2, KRAS, NEU1, PIK3CA
3MP:00053888.2CTNNBIP1, ERBB2, FGFR2, KRAS, MUT, NEU1
4MP:00053708.0APC, FGFR2, GLUL, KLF6, KRAS, MUT
5MP:00053898.0APC, CDH1, ERBB2, FGFR2, KLF6, KRAS
6MP:00028737.9APC, CDH1, ERBB2, FGFR2, GLUL, IRF1
7MP:00053677.9APC, CTNNBIP1, FGFR2, IRF1, KRAS, MUT
8MP:00020067.9APC, CDH1, ERBB2, FGFR2, IRF1, KRAS
9MP:00053807.6APC, CDH1, CTNNBIP1, ERBB2, FGFR2, KLF6
10MP:00053907.5APC, CTNNBIP1, ERBB2, FGFR2, IRF1, KRAS
11MP:00053817.5APC, CDH1, CTNNBIP1, ERBB2, FGFR2, KRAS
12MP:00107717.3APC, CDH1, ERBB2, FGFR2, IRF1, KLF6
13MP:00053797.2APC, CDH1, ERBB2, FGFR2, IRF1, KLF6
14MP:00036316.7APC, CTNNBIP1, ERBB2, FGFR2, GLUL, KRAS
15MP:00053876.6APC, CDH1, FGFR2, IRF1, KRAS, MUT
16MP:00053856.2APC, CDH1, ERBB2, FGFR2, IRF1, KLF6
17MP:00053766.0APC, CDH1, ERBB2, FGFR2, GLUL, IRF1
18MP:00053785.5APC, CDH1, CTNNBIP1, ERBB2, FGFR2, GLUL
19MP:00053845.3APC, CDH1, CTNNBIP1, ERBB2, FGFR2, GLUL
20MP:00107685.1APC, CDH1, CTNNBIP1, ERBB2, FGFR2, GLUL

Publications for Gastric Cancer, Somatic

About this section

Variations for Gastric Cancer, Somatic

About this section

UniProtKB/Swiss-Prot genetic disease variations for Gastric Cancer, Somatic:

67 (show all 17)
id Symbol AA change Variation ID SNP ID
1APCp.Gly817CysVAR_005035
2APCp.Ile880ThrVAR_005036
3APCp.Asn942AspVAR_005039
4APCp.Gly1120GluVAR_005042rs28933379
5APCp.Arg1171HisVAR_005043
6APCp.Phe1197SerVAR_005045
7APCp.Ile1259ThrVAR_005046
8APCp.Gly1312GluVAR_005050
9APCp.Val1326AlaVAR_005052
10CASP10p.Met147ThrVAR_037428rs121909776
11IRF1p.Met8LeuVAR_065134
12IRF1p.Trp11ArgVAR_065135
13KRASp.Gly12ValVAR_006840
14KRASp.Ala59ThrVAR_016030
15KRASp.Lys5AsnVAR_064849
16MUTYHp.Pro402SerVAR_026049
17MUTYHp.Gln411ArgVAR_026050

Clinvar genetic disease variations for Gastric Cancer, Somatic:

5 (show all 17)
id Gene Variation Type Significance SNP ID Assembly Location
1CDH1NM_004360.4(CDH1): c.2494G> A (p.Val832Met)single nucleotide variantLikely pathogenic, Pathogenicrs35572355GRCh37Chr 16, 68867247: 68867247
2KRASNM_033360.3(KRAS): c.35G> A (p.Gly12Asp)single nucleotide variantPathogenicrs121913529GRCh37Chr 12, 25398284: 25398284
3KRASNM_033360.3(KRAS): c.34G> A (p.Gly12Ser)single nucleotide variantPathogenicrs121913530GRCh37Chr 12, 25398285: 25398285
4TP53NM_000546.5(TP53): c.847C> T (p.Arg283Cys)single nucleotide variantLikely pathogenicrs149633775GRCh37Chr 17, 7577091: 7577091
5FGFR2NM_000141.4(FGFR2): c.799T> C (p.Ser267Pro)single nucleotide variantPathogenicrs121918505GRCh37Chr 10, 123279633: 123279633
6PIK3CANM_006218.2(PIK3CA): c.3140A> G (p.His1047Arg)single nucleotide variantPathogenicrs121913279GRCh37Chr 3, 178952085: 178952085
7PIK3CANM_006218.2(PIK3CA): c.1633G> A (p.Glu545Lys)single nucleotide variantPathogenicrs104886003GRCh37Chr 3, 178936091: 178936091
8PIK3CANM_006218.2(PIK3CA): c.3203dupA (p.Asn1068Lysfs)duplicationPathogenicrs587776802GRCh37Chr 3, 178952148: 178952148
9ERBB2NM_001005862.2(ERBB2): c.2236G> A (p.Gly746Ser)single nucleotide variantPathogenicrs28933369GRCh37Chr 17, 37880997: 37880997
10IRF1NM_002198.2(IRF1): c.22A> T (p.Met8Leu)single nucleotide variantPathogenicrs121912469GRCh37Chr 5, 131825149: 131825149
11MUTYHNM_001128425.1(MUTYH): c.1213C> T (p.Pro405Ser)single nucleotide variantPathogenicrs121908382GRCh37Chr 1, 45797202: 45797202
12MUTYHNM_001128425.1(MUTYH): c.1241A> G (p.Gln414Arg)single nucleotide variantPathogenicrs121908383GRCh37Chr 1, 45797174: 45797174
13KLF6NM_001300.5(KLF6): c.465C> A (p.Ser155Arg)single nucleotide variantPathogenicrs121909144GRCh37Chr 10, 3824044: 3824044
14CASP10NM_032977.3(CASP10): c.769C> T (p.Gln257Ter)single nucleotide variantPathogenicrs121909775GRCh37Chr 2, 202070652: 202070652
15CASP10NM_032977.3(CASP10): c.440T> C (p.Met147Thr)single nucleotide variantPathogenicrs121909776GRCh37Chr 2, 202052521: 202052521
16APCNM_000038.5(APC): c.3359G> A (p.Gly1120Glu)single nucleotide variantPathogenicrs28933379GRCh37Chr 5, 112174650: 112174650
17APCNM_000038.5(APC): c.3199C> T (p.Gln1067Ter)single nucleotide variantPathogenicrs137854571GRCh37Chr 5, 112174490: 112174490

Cosmic variations for Gastric Cancer, Somatic:

7 (show top 50)    (show all 2317)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
1COSM43606TP53stomach,NS,carcinoma,adenocarcinoma3
2COSM43606TP53stomach,NS,carcinoma,adenocarcinoma3
3COSM43606TP53stomach,NS,carcinoma,adenocarcinoma3
4COSM43642TP53stomach,NS,carcinoma,adenocarcinoma3
5COSM43606TP53stomach,NS,carcinoma,adenocarcinoma3
6COSM43606TP53stomach,NS,carcinoma,adenocarcinoma3
7COSM43597TP53stomach,NS,carcinoma,adenocarcinoma3
8COSM43597TP53stomach,NS,carcinoma,adenocarcinoma3
9COSM43597TP53stomach,NS,carcinoma,adenocarcinoma3
10COSM43606TP53stomach,NS,carcinoma,adenocarcinoma3
11COSM43642TP53stomach,NS,carcinoma,adenocarcinoma3
12COSM43642TP53stomach,NS,carcinoma,adenocarcinoma3
13COSM43650TP53stomach,NS,carcinoma,adenocarcinoma3
14COSM43650TP53stomach,NS,carcinoma,adenocarcinoma3
15COSM43650TP53stomach,NS,carcinoma,adenocarcinoma3
16COSM43657TP53stomach,NS,carcinoma,adenocarcinoma3
17COSM43650TP53stomach,NS,carcinoma,adenocarcinoma3
18COSM43650TP53stomach,NS,carcinoma,adenocarcinoma3
19COSM43642TP53stomach,NS,carcinoma,adenocarcinoma3
20COSM43642TP53stomach,NS,carcinoma,adenocarcinoma3
21COSM43642TP53stomach,NS,carcinoma,adenocarcinoma3
22COSM43650TP53stomach,NS,carcinoma,adenocarcinoma3
23COSM43568TP53stomach,NS,carcinoma,adenocarcinoma3
24COSM43568TP53stomach,NS,carcinoma,adenocarcinoma3
25COSM11501TP53stomach,NS,carcinoma,adenocarcinoma3
26COSM11564TP53small intestine,NS,carcinoma,adenocarcinoma3
27COSM11564TP53small intestine,NS,carcinoma,adenocarcinoma3
28COSM43541TP53stomach,NS,carcinoma,adenocarcinoma3
29COSM11501TP53stomach,NS,carcinoma,adenocarcinoma3
30COSM11501TP53stomach,NS,carcinoma,adenocarcinoma3
31COSM11306TP53stomach,NS,carcinoma,adenocarcinoma3
32COSM11307TP53stomach,NS,carcinoma,adenocarcinoma3
33COSM11307TP53stomach,NS,carcinoma,adenocarcinoma3
34COSM11307TP53stomach,NS,carcinoma,adenocarcinoma3
35COSM43541TP53stomach,NS,carcinoma,adenocarcinoma3
36COSM43541TP53stomach,NS,carcinoma,adenocarcinoma3
37COSM43559TP53stomach,NS,carcinoma,adenocarcinoma3
38COSM43559TP53stomach,NS,carcinoma,adenocarcinoma3
39COSM43559TP53stomach,NS,carcinoma,adenocarcinoma3
40COSM43568TP53stomach,NS,carcinoma,adenocarcinoma3
41COSM43559TP53stomach,NS,carcinoma,adenocarcinoma3
42COSM43559TP53stomach,NS,carcinoma,adenocarcinoma3
43COSM43555TP53stomach,NS,carcinoma,adenocarcinoma3
44COSM43555TP53stomach,NS,carcinoma,adenocarcinoma3
45COSM43555TP53stomach,NS,carcinoma,adenocarcinoma3
46COSM43559TP53stomach,NS,carcinoma,adenocarcinoma3
47COSM43657TP53stomach,NS,carcinoma,adenocarcinoma3
48COSM43657TP53stomach,NS,carcinoma,adenocarcinoma3
49COSM43726TP53stomach,NS,carcinoma,adenocarcinoma3
50COSM43726TP53stomach,NS,carcinoma,adenocarcinoma3

Expression for genes affiliated with Gastric Cancer, Somatic

About this section
Search GEO for disease gene expression data for Gastric Cancer, Somatic.

Pathways for genes affiliated with Gastric Cancer, Somatic

About this section

Pathways related to Gastric Cancer, Somatic according to GeneCards Suite gene sharing:

(show all 30)
idSuper pathwaysScoreTop Affiliating Genes
19.8FGFR2, PIK3CA
2
Show member pathways
9.4FGFR2, PIK3CA
3
Show member pathways
9.4ERBB2, FGFR2, KRAS
49.4IRF1, KRAS, PIK3CA
5
Show member pathways
9.3ERBB2, KRAS, PIK3CA
6
Show member pathways
9.3ERBB2, KRAS, PIK3CA
79.3CDH1, PIK3CA
89.3CDH1, PIK3CA
9
Show member pathways
9.2CASP10, IRF1, KRAS, PIK3CA
10
Show member pathways
9.2APC, ERBB2, FGFR2, KRAS
119.1APC, CASP10, CDH1
129.1APC, FGFR2, KRAS, PIK3CA
13
Show member pathways
9.1APC, FGFR2, KRAS, PIK3CA
149.1APC, ERBB2, KRAS, PIK3CA
15
Show member pathways
9.1ERBB2, IRF1, KRAS, PIK3CA
169.1CASP10, CDH1, ERBB2
179.0ERBB2, FGFR2, KRAS, PIK3CA
189.0CDH1, FGFR2, PIK3CA
199.0APC, CDH1, KRAS
208.9CDH1, ERBB2, PIK3CA
218.9CDH1, ERBB2, KRAS
228.9APC, CDH1, CTNNBIP1
238.8APC, CASP10, ERBB2, KRAS, PIK3CA
24
Show member pathways
8.8CASP10, ERBB2, FGFR2, KRAS, PIK3CA
25
Show member pathways
8.8APC, ERBB2, FGFR2, KRAS, PIK3CA
26
Show member pathways
8.5CDH1, ERBB2, KRAS, PIK3CA
27
Show member pathways
8.3APC, CDH1, ERBB2, KRAS, PIK3CA
28
Show member pathways
8.3APC, CDH1, ERBB2, KRAS, PIK3CA
29
Show member pathways
8.2CDH1, ERBB2, FGFR2, KRAS, PIK3CA
308.0APC, CDH1, ERBB2, FGFR2, KRAS, PIK3CA

GO Terms for genes affiliated with Gastric Cancer, Somatic

About this section

Cellular components related to Gastric Cancer, Somatic according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1lateral plasma membraneGO:00163289.4APC, CDH1

Biological processes related to Gastric Cancer, Somatic according to GeneCards Suite gene sharing:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1regulation of multicellular organism growthGO:004001410.1FGFR2, PIK3CA
2regulation of ERK1 and ERK2 cascadeGO:007037210.1ERBB2, FGFR2
3cellular component disassembly involved in execution phase of apoptosisGO:000692110.0APC, CDH1
4ERBB2 signaling pathwayGO:00381289.8ERBB2, KRAS, PIK3CA
5fibroblast growth factor receptor signaling pathwayGO:00085439.4ERBB2, FGFR2, KRAS, PIK3CA
6insulin receptor signaling pathwayGO:00082869.3ERBB2, FGFR2, KRAS, PIK3CA
7innate immune responseGO:00450878.8CASP10, ERBB2, FGFR2, KRAS, PIK3CA

Molecular functions related to Gastric Cancer, Somatic according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1gamma-catenin bindingGO:00452959.4APC, CDH1

Sources for Gastric Cancer, Somatic

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet